MaxCyte, Inc. Business Combination, Contingent Consideration, Liability, Noncurrent
MaxCyte, Inc. (MXCT) had Business Combination, Contingent Consideration, Liability, Noncurrent of $25.00 thousand as of 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent · last filed 2025-11-13
- 2025-09-30: Business Combination, Contingent Consideration, Liability, Noncurrent $25.00K.
- 2025-06-30: Business Combination, Contingent Consideration, Liability, Noncurrent $25.00K.
| Period end | Business Combination, Contingent Consideration, Liability, Noncurrent |
|---|---|
| 2025-09-30 | $25.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $25.00K 10-Q · filed 2025-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |